<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00711100</url>
  </required_header>
  <id_info>
    <org_study_id>Study 1</org_study_id>
    <secondary_id>1R01CA135884</secondary_id>
    <nct_id>NCT00711100</nct_id>
  </id_info>
  <brief_title>Evaluation of Oral Tobacco as a Harm Reduction Method for Smokers</brief_title>
  <official_title>Preference, Health Effects and Efficacy of Four Oral Tobacco Products for Smoking Cessation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently, tobacco companies have developed new oral tobacco products that are purportedly
      less harmful than conventional tobacco products. These products have not been tested by
      independent research for their health effects or consumer palatability. In addition, it is
      not known if these products will be used in addition to cigarette smoking or as a substitute
      to cigarettes. These two studies will examine four oral tobacco products to answer some of
      these questions.

      The goals of this first study will be to examine: 1) the brand of oral tobacco products which
      is preferred by cigarette smokers and the pattern and amount of product use when used as a
      switching tool; 2) the characteristics that are associated with product choice; 3) nicotine
      exposure from these products; and 4) the withdrawal symptoms from the tobacco products and
      potential for continued use.

      Specifically, our primary aims hypotheses were: 1) the product that will be chosen by most
      smokers will be based on taste and sensory aspects of the product with products higher in
      nicotine content more likely to be chosen as the preferred product; and 2) subjects will
      experience no difficulty using the product for complete cigarette substitution, but a small
      minority will engage in dual product use.

      For the secondary aims, we hypothesized: 1) that compared to the subjects' own brand of
      cigarettes, the biomarkers for exposure for the oral tobacco products will be significantly
      lower; 2) withdrawal symptoms from the oral products are likely to occur, but are likely to
      be mild compared to cigarette withdrawal.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be accomplished by allowing subjects to sample the products and choose one
      oral tobacco product that they will use instead of cigarettes for a two week period. After
      the two weeks, they will discontinue all tobacco use and withdrawal symptoms and abstinence
      rates will be observed.

      Subjects will attend an orientation visit where the study will be explained in detail.
      Interested subjects will sign a consent form and be scheduled to return for baseline
      measures. Subjects will have a review of medical history to verify that they are in generally
      good health and do not have contraindications to the study products. Eligible subjects will
      collect one week of baseline measures while smoking at their normal rate: measures include
      daily diaries of smoking, questionnaires and urine samples. At the second baseline visit,
      they will receive samples of the oral tobacco products. The tobacco products tested are five
      novel oral products recently introduced to the market: 1) Camel Snus (higher nicotine); 2)
      General Snus (higher nicotine); 3) Marlboro Snus (lower nicotine); and two compressed tobacco
      tablets, 4) Ariva (lower nicotine), or 5) Stonewall (higher nicotine). All of these tobacco
      products are purported to have reduced levels of tobacco-specific nitrosamines.

      During sample weeks, subjects will be given 10 pouches/tablets of each product in a
      within-subject design and instructed to use at least three of the daily products in the
      morning of sample day and resume smoking in the afternoon and through the following day. They
      will sample the next product in a similar manner. The order of product was randomized. All
      subjects will sample all five products. This design will allow a short, but adequate trial of
      each product to determine preference. After the sampling weeks, subjects will choose the
      product they will want to use to quit smoking. They will be supplied that product over the
      next two weeks.

      During the two weeks of product use during smoking abstinence, subjects will come to weekly
      clinic visits and then a follow-up visits at 1 week and a phone call at 4 weeks after the end
      of treatment. At baseline, and 2 weeks post cigarette cessation, subjects will bring in a
      urine sample from their first morning void and bloods will be drawn. At each visit, subjects
      will have vital signs obtained (blood pressure, heart rate, weight and carbon monoxide
      level), they will complete several subjective forms regarding tobacco use, withdrawal
      symptoms, and mood. Subjects will receive brief behavioral counseling for smoking cessation
      at all visits.

      In addition, during the sample weeks and at the end of two weeks of study product use,
      subjects will submit three used chews that will be sent to CDC to be analyzed for the tobacco
      constituents.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open label trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Product Preference</measure>
    <time_frame>2 weeks</time_frame>
    <description>Number of individuals who selected each of the products (e.g., Camel Snus, Marlboro Snus, General Snus, Ariva, Stonewall).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Abstinence From Cigarettes</measure>
    <time_frame>Survival (abstinence) at 3 weeks (2 weeks intervention and 1 week follow-up)</time_frame>
    <description>Abstinence from cigarettes during Abstinence Phase.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Tobacco Use Disorder</condition>
  <arm_group>
    <arm_group_label>Camel Snus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Camel Snus (oral smokeless tobacco product). Dosage: 1.74-1.97 mg nicotine per portion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Marlboro Snus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Marlboro Snus (oral smokeless tobacco product). Dosage: 0.14 - 0.38 mg nicotine per portion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stonewall</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stonewall (oral dissolvable tobacco product). Dosage: 0.28-0.57 mg nicotine per portion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ariva</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ariva (oral dissolvable tobacco product). Dosage: 0.24-0.25 mg nicotine per portion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>General Snus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>General Snus (oral smokeless tobacco product); Dosage: 3.37 mg nicotine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Camel Snus</intervention_name>
    <description>All subjects will sample Camel Snus and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Camel Snus. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Camel Snus is chosen for use) during abstinence phase.</description>
    <arm_group_label>Camel Snus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Marlboro Snus</intervention_name>
    <description>All subjects will sample Marlboro Snus and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Marlboro Snus. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Marlboro Snus is chosen for use) during abstinence phase.</description>
    <arm_group_label>Marlboro Snus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stonewall</intervention_name>
    <description>All subjects will sample Stonewall and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Stonewall. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Stonewall is chosen for use) during abstinence phase.</description>
    <arm_group_label>Stonewall</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ariva</intervention_name>
    <description>All subjects will sample Ariva and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Ariva. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Ariva is chosen for use) during abstinence phase.</description>
    <arm_group_label>Ariva</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>General Snus</intervention_name>
    <description>All subjects will sample General Snus and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of General Snus. Intervention period (duration: 2 weeks) involves ad libitum daily use (if General Snus is chosen for use) during abstinence phase.</description>
    <arm_group_label>General Snus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cigarette smokers who smoke 10 or more cigarettes per day

          -  Generally good health

        Exclusion Criteria:

          -  Unstable medical or psychiatric condition.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dorothy Hatsukami, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univeristy of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Research Institute</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>47404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2008</study_first_submitted>
  <study_first_submitted_qc>July 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2008</study_first_posted>
  <results_first_submitted>October 17, 2013</results_first_submitted>
  <results_first_submitted_qc>August 14, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 16, 2015</results_first_posted>
  <last_update_submitted>April 6, 2017</last_update_submitted>
  <last_update_submitted_qc>April 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Substitution for cigarettes</keyword>
  <keyword>Oral tobacco products</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited 10/2008 through 8/2009 through local advertisements in Minnesota and Oregon.</recruitment_details>
      <pre_assignment_details>Sampling Phase preceded the 2 week Abstinence Phase. Sampling phase involved sampling each study product for a 1/2 day; subjects then chose the product that they would like to use for a two week cigarette abstinence period</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Oral Tobacco Products</title>
          <description>Camel Snus, Marlboro Snus, General Snus, Stonewall, Ariva</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oral Tobacco Products</title>
          <description>Camel Snus, Marlboro Snus, General Snus, Stonewall, Ariva</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="104"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.1" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Product Preference</title>
        <description>Number of individuals who selected each of the products (e.g., Camel Snus, Marlboro Snus, General Snus, Ariva, Stonewall).</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Camel Snus</title>
            <description>Number of participants who sampled Camel Snus</description>
          </group>
          <group group_id="O2">
            <title>Marlboro Snus</title>
            <description>Number of participants who sampled Marlboro Snus</description>
          </group>
          <group group_id="O3">
            <title>Stonewall</title>
            <description>Number of participants who sampled Stonewall</description>
          </group>
          <group group_id="O4">
            <title>Ariva</title>
            <description>Number of participants who sampled Ariva</description>
          </group>
          <group group_id="O5">
            <title>General Snus</title>
            <description>Number of partiicipants who sampled General Snus</description>
          </group>
        </group_list>
        <measure>
          <title>Product Preference</title>
          <description>Number of individuals who selected each of the products (e.g., Camel Snus, Marlboro Snus, General Snus, Ariva, Stonewall).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="98"/>
                <count group_id="O4" value="98"/>
                <count group_id="O5" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Abstinence From Cigarettes</title>
        <description>Abstinence from cigarettes during Abstinence Phase.</description>
        <time_frame>Survival (abstinence) at 3 weeks (2 weeks intervention and 1 week follow-up)</time_frame>
        <population>At the end of Sampling Phase, subjects chose a preferred product to use during a two week Abstinence Phase. Abstinence from cigarettes was determined during the 2 week study product phase (e.g., Abstinence Phase) and 1 week after this phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Camel Snus</title>
            <description>Number of participants who preferred this product during abstinence phase</description>
          </group>
          <group group_id="O2">
            <title>Marlboro Snus</title>
            <description>Number of participants who preferred this product during abstinence phase</description>
          </group>
          <group group_id="O3">
            <title>Stonewall</title>
            <description>Number of participants who preferred this product during abstinence phase</description>
          </group>
          <group group_id="O4">
            <title>Ariva</title>
            <description>Number of participants who preferred this product during abstinence phase</description>
          </group>
        </group_list>
        <measure>
          <title>Abstinence From Cigarettes</title>
          <description>Abstinence from cigarettes during Abstinence Phase.</description>
          <population>At the end of Sampling Phase, subjects chose a preferred product to use during a two week Abstinence Phase. Abstinence from cigarettes was determined during the 2 week study product phase (e.g., Abstinence Phase) and 1 week after this phase.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Camel Snus</title>
          <description>Participant who sampled Camel Snus</description>
        </group>
        <group group_id="E2">
          <title>Marlboro Snus</title>
          <description>Participants who sampled Marlboro Snus</description>
        </group>
        <group group_id="E3">
          <title>Stonewall</title>
          <description>Participants who sampled Stonewall</description>
        </group>
        <group group_id="E4">
          <title>Ariva</title>
          <description>Participants who sampled Ariva</description>
        </group>
        <group group_id="E5">
          <title>General Snus</title>
          <description>Participants who sampled General Snus</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Excessive Salivation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E5" events="14" subjects_affected="14" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Dizziness/Lightheadedness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dorothy Hatsukami, Ph.D.</name_or_title>
      <organization>University_of_Minnesota</organization>
      <phone>612-626-2121</phone>
      <email>hatsu001@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

